‘Covid is all about privilege’: Trump’s care underscores health inequalities
Trump’s experience is a world away from the stressful waiting game most patients wade through after a positive test.
Related Articles
Pharmalittle: We’re reading about Medicare drug negotiations, a Novartis malaria drug, and more
The pharmaceutical industry is criticizing the Trump administration’s plan for carrying out a critical round of Medicare drug price negotiations
Novartis wins approval for newborn malaria treatment
And other biotech news, brought to you by The Readout.
How Republicans sidelined the health care industry and pushed through historic Medicaid cuts
The passage of President Trump’s signature tax cut bill shows how the health care industry’s influence is waning.
Leading medical groups sue Kennedy over changed Covid-19 vaccine recommendations
Six major medical groups, and a pregnant physician, are suing HHS Secretary Robert F. Kennedy Jr. over changes he made to Covid-19 vaccine recommendations.
Leading medical groups sue Kennedy over changed Covid-19 vaccine recommendations
Six major medical groups, and a pregnant physician, are suing HHS Secretary Robert F. Kennedy Jr. over changes he made to Covid-19 vaccine recommendations.
Cogent Biosciences drug improves symptoms of chronic immune disorder, study results show
Cogent Biosciences said its experimental drug reduced the symptoms of a chronic immune disorder called indolent systemic mastocytosis.
Novo Nordisk ends deal with Hims due to compounding concerns with obesity drugs
Novo Nordisk is ending a deal with telehealth company Hims & Hers, saying Monday that Hims has been engaging in “illegal mass compounding” of GLP-1…
Health care costs: one of the biggest obstacles to reshoring American industry
If the U.S. is serious about reshoring manufacturing jobs, it needs to address the factors that lead to offshoring those jobs in the first place,…
FDA chief’s goals of ‘radical transparency’ threatened by agency cuts
FDA chief wants more transparency and fewer conflicts of interest. Staff warn cuts may do the opposite.
The decades-long journey to Gilead’s twice-a-year HIV prevention drug lenacapavir
Gilead’s twice-a-year HIV prevention drug lenacapavir is 30 years in the making. Here’s the story behind it.